A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis

Exclusion Criteria

• •1. A FEV1/FVC ratio less than 0.70 at the time of screening (postbronchodilator)
• •2. The extent of emphysema on the HRCT is greater than the extent of fibrosis.
• •3. Currently listed for lung transplantation
• •4. Use of the following medications:
• •1. Immunosuppressive medications (eg, methotrexate, cyclosporine, azathioprine, intramuscular long-acting depot corticosteroid) within 3 months prior to Visit 1 (screening). Oral prednisone \<= 15 mg/day (or equivalent oral corticosteroid) is allowed for chronic use if subject was on a stable dose at least 30 days prior to Visit 1 (screening)
• •2. Pirfenidone within 4 weeks prior to Visit 1 (screening)
• •3. N-acetylcysteine within 4 weeks prior to Visit 1 (screening)
• •4. Live attenuated vaccines within 4 weeks prior to Visit 1 (screening)